Vertex Pharmaceuticals Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $345.41
- Today's High:
- $348.99
- Open Price:
- $348.27
- 52W Low:
- $276.57
- 52W High:
- $367
- Prev. Close:
- $347.22
- Volume:
- 590540
Company Statistics
- Market Cap.:
- $89.62 billion
- Book Value:
- 60.01
- Revenue TTM:
- $9.51 billion
- Operating Margin TTM:
- 47.04%
- Gross Profit TTM:
- $5.32 billion
- Profit Margin:
- 35.4%
- Return on Assets TTM:
- 15.56%
- Return on Equity TTM:
- 24.56%
Company Profile
Vertex Pharmaceuticals Inc had its IPO on 1991-07-24 under the ticker symbol VRTX.
The company operates in the Healthcare sector and Biotechnology industry. Vertex Pharmaceuticals Inc has a staff strength of 4,800 employees.
Stock update
Shares of Vertex Pharmaceuticals Inc opened at $348.27 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $345.41 - $348.99, and closed at $346.55.
This is a -0.19% slip from the previous day's closing price.
A total volume of 590,540 shares were traded at the close of the day’s session.
In the last one week, shares of Vertex Pharmaceuticals Inc have slipped by -1.3%.
Vertex Pharmaceuticals Inc's Key Ratios
Vertex Pharmaceuticals Inc has a market cap of $89.62 billion, indicating a price to book ratio of 6.1509 and a price to sales ratio of 9.0986.
In the last 12-months Vertex Pharmaceuticals Inc’s revenue was $9.51 billion with a gross profit of $5.32 billion and an EBITDA of $4.63 billion. The EBITDA ratio measures Vertex Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Vertex Pharmaceuticals Inc’s operating margin was 47.04% while its return on assets stood at 15.56% with a return of equity of 24.56%.
In Q2, Vertex Pharmaceuticals Inc’s quarterly earnings growth was a positive 12.5% while revenue growth was a positive 13.5%.
Vertex Pharmaceuticals Inc’s PE and PEG Ratio
- Forward PE
- 19.7239
- Trailing PE
- 26.9163
- PEG
- 0.4128
Its diluted EPS in the last 12-months stands at $12.9 per share while it has a forward price to earnings multiple of 19.7239 and a PEG multiple of 0.4128. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Vertex Pharmaceuticals Inc’s profitability.
Vertex Pharmaceuticals Inc stock is trading at a EV to sales ratio of 8.1831 and a EV to EBITDA ratio of 16.8377. Its price to sales ratio in the trailing 12-months stood at 9.0986.
Vertex Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $20.35 billion
- Total Liabilities
- $3.35 billion
- Operating Cash Flow
- $-303900000.00
- Capital Expenditure
- $59.60 million
- Dividend Payout Ratio
- 0%
Vertex Pharmaceuticals Inc ended 2024 with $20.35 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $20.35 billion while shareholder equity stood at $15.47 billion.
Vertex Pharmaceuticals Inc ended 2024 with $0 in deferred long-term liabilities, $3.35 billion in other current liabilities, 257800000.00 in common stock, $8.14 billion in retained earnings and $1.09 billion in goodwill. Its cash balance stood at $10.15 billion and cash and short-term investments were $11.24 billion. The company’s total short-term debt was $0 while long-term debt stood at $0.
Vertex Pharmaceuticals Inc’s total current assets stands at $13.87 billion while long-term investments were $1.36 billion and short-term investments were $11.24 billion. Its net receivables were $1.56 billion compared to accounts payable of $363.00 million and inventory worth $603.50 million.
In 2024, Vertex Pharmaceuticals Inc's operating cash flow was $-303900000.00 while its capital expenditure stood at $59.60 million.
Comparatively, Vertex Pharmaceuticals Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $346.55
- 52-Week High
- $367
- 52-Week Low
- $276.57
- Analyst Target Price
- $379.92
Vertex Pharmaceuticals Inc stock is currently trading at $346.55 per share. It touched a 52-week high of $367 and a 52-week low of $367. Analysts tracking the stock have a 12-month average target price of $379.92.
Its 50-day moving average was $349.39 and 200-day moving average was $324.56 The short ratio stood at 2.31 indicating a short percent outstanding of 0%.
Around 16.5% of the company’s stock are held by insiders while 9654.8% are held by institutions.
Frequently Asked Questions About Vertex Pharmaceuticals Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO and SYMDEKO/SYMKEVI for people with CF with at least one F508del mutation for 6 years of age or older; ORKAMBI for CF homozygous F508del mutation for CF patients 2 year or older; and KALYDECO for the treatment of patients with 4 months or older who have CF with a mutation that is responsive to ivacaftor, and R117H mutation or one of certain gating mutations. The company’s pipeline includes VX-522, a CF mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial; and VX-864 for treatment of AAT deficiency, which is in Phase 2 clinical trial. In addition, it provides VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sell the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies or pharmacy chains, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Affinia Therapeutics; Arbor Biotechnologies, Inc.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Obsidian Therapeutics, Inc.; Verve Therapeutics; Skyhawk Therapeutics; and Ribometrix, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.